Nursing Elites

1. A client with breast cancer is receiving cyclophosphamide. Which of the following findings should the nurse monitor?

• A. Hypertension
• B. Hyperglycemia
• C. Ototoxicity
• D. Hemorrhagic cystitis

Correct answer: D

Rationale: The nurse should monitor the client for hemorrhagic cystitis when receiving cyclophosphamide due to its potential to cause bladder irritation and lead to this serious adverse effect. It is essential to assess for symptoms such as hematuria, dysuria, and flank pain. Monitoring for hypertension, hyperglycemia, and ototoxicity is not directly related to the side effects of cyclophosphamide.

2. A client has a new prescription for Nitroglycerin to treat angina. Which of the following instructions should be included?

• A. Take this medication only when experiencing chest pain.
• B. Store the medication in a cool, dry place.
• C. Apply the patch to a different site each time.
• D. Do not cut the patch regardless of your blood pressure.

Correct answer: C

Rationale: When using Nitroglycerin patches to treat angina, it is crucial to apply the patch to a different site each time. This practice helps prevent skin irritation and ensures proper absorption of the medication, optimizing its effectiveness in managing angina symptoms.

3. A client has a new prescription for Filgrastim to treat neutropenia. Which of the following statements should the nurse include?

• A. This medication will help increase your white blood cell count.
• B. This medication will help reduce your risk of infection.
• C. This medication will help improve your red blood cell count.
• D. This medication will help increase your platelet count.

Correct answer: A

Rationale: The correct statement the nurse should include is that 'This medication will help increase your white blood cell count.' Filgrastim is a medication used to stimulate the production of white blood cells, specifically neutrophils, to increase the white blood cell count. This increase in white blood cells helps reduce the risk of infections in clients with neutropenia. Choices B, C, and D are incorrect because Filgrastim specifically targets white blood cells, not red blood cells or platelets.

4. A client has a new prescription for Cyclobenzaprine to treat muscle spasms. Which of the following instructions should the nurse include in the teaching?

• A. Avoid driving or operating heavy machinery while taking this medication.
• B. Take this medication on an empty stomach for best results.
• C. Take this medication only when experiencing muscle pain.
• D. Increase your intake of potassium-rich foods while taking this medication.

Correct answer: A

Rationale: The correct instruction that the nurse should include in the teaching for a client prescribed Cyclobenzaprine is to avoid driving or operating heavy machinery while taking this medication. Cyclobenzaprine can cause drowsiness, so it is important to advise clients to avoid activities that require alertness and coordination to prevent accidents or injuries. Choice B is incorrect because Cyclobenzaprine can be taken with or without food. Choice C is incorrect because Cyclobenzaprine is typically taken regularly as prescribed, not just when experiencing muscle pain. Choice D is incorrect because there is no specific need to increase potassium-rich foods while taking Cyclobenzaprine.

5. A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?

• A. Warm the medication to room temperature before administering.
• B. Administer the medication by IV bolus over 5 minutes.
• C. Dilute the medication in a 5% dextrose and water solution.
• D. Monitor the client for hypersensitivity reactions.

Correct answer: D

Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.

Similar Questions